<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754440</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-5059</org_study_id>
    <nct_id>NCT02754440</nct_id>
  </id_info>
  <brief_title>Evaluation of Trima Version 7.0 Platelets in PAS</brief_title>
  <official_title>Evaluation of the Performance of Trima Accel® Version 7.0 Software Enhancements for the Collection of Platelets Stored in Platelet Additive Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo BCT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify that platelets collected on the Trima Accel system with Version 7.0 software
      enhancements and stored in platelet additive solution (PAS) meet the FDA requirements for
      leukoreduction (&lt; 5.0 × 10^6 residual white blood cells [WBC] per transfusable unit).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate changes to the Trima Accel software to ensure the modified
      software meets the FDA acceptance criteria for leukoreduction and platelet yield. The
      operating range for the system flow rates, anticoagulant ratios, storage conditions, and
      centrifugal forces are the same as the currently cleared Trima Accel system. There are no
      changes to the environment or storage conditions for platelets, therefore, no in vitro or in
      vivo platelet quality data will be collected.

      This is a prospective, open-label, multi-center controlled study to evaluate the
      leukoreduction of platelets stored in platelet additive solution (PAS) collected on the
      Trima Accel system Version 7.0 software enhancement. Up to 350 healthy adult subjects will
      be enrolled in this study to ensure 93 single, 93 double and 93 triple platelet product
      evaluable data points. Evaluable is defined as a completed platelet product that does not
      meet any of the protocol analysis exclusion criteria.

      Plateletpheresis will be per site standard practice and per applicable FDA guidelines such
      as the FDA Collection of Platelets by Automated Methods, December 2007 Guidance for Industry
      and Pre-storage Leukocyte Reduction of Whole Blood and Blood Components Intended for
      Transfusion, September 2012.

      Study participation will be up to 30 days and will consist of 1 to 2 visits. Screening may
      be done within 30 days before the apheresis procedure or combined as a single visit, which
      includes screening and the apheresis procedure all in 1 day.

      The entire study should be completed in approximately 16 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Product Residual White Blood Cells (WBC)</measure>
    <time_frame>Within 48 hours of end of donation</time_frame>
    <description>The proportion of platelet units with an acceptable residual WBC level. Acceptable residual WBC counts are: singles = residual WBC level &lt; 5.0 × 10^6; doubles = residual WBC level &lt; 8.0 × 10^6 or &lt; 5.0 × 10^6 for each transfusable unit; and triples = residual WBC level &lt; 12.0 × 10^6 or &lt; 5.0 × 10^6 for each transfusable unit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Product Platelet yield</measure>
    <time_frame>Within 48 hours of end of donation</time_frame>
    <description>The proportion of platelet units with an acceptable platelet yield. Acceptable platelet yield for single, double and triple platelet products are: platelet yield ≥ 3.0 × 10^11 for singles, platelet yield ≥ 6.2 × 10^11 for doubles, and platelet yield ≥ 9.3 × 10^11 for triples.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Platelet Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Platelet Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Platelet Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trima Accel System with Version 7.0 Software</intervention_name>
    <description>Platelet Apheresis Procedure</description>
    <arm_group_label>Single Platelet Product</arm_group_label>
    <arm_group_label>Double Platelet Product</arm_group_label>
    <arm_group_label>Triple Platelet Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older.

          -  Meets the inclusion criteria defined by the Blood Center for an apheresis platelet
             with PAS collection on the Trima Accel system. These criteria are based on FDA
             guidance and American Association of Blood Banks (AABB) standards. Note: subjects who
             are deferred from volunteer community donations because of travel restrictions,
             piercings, or tattoos may participate in the study, as products are not transfused.

          -  Has given written informed consent.

        Exclusion Criteria:

          -  Has previously donated an evaluable platelet product in this study (CTS 5059).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Pidcoke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Terumo BCT, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Rhodes</last_name>
    <phone>(303) 231-4088</phone>
    <email>diane.rhodes@terumobct.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Diego Blood Bank</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Villa, RN</last_name>
      <phone>619-400-8150</phone>
      <email>jvilla@sandiegobloodbank.org</email>
    </contact>
    <contact_backup>
      <last_name>Will Davey</last_name>
      <phone>619-400-8318</phone>
      <email>wdavey@sandiegobloodbank.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Tressler, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bonfils Blood Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nero Evero</last_name>
      <phone>303-341-4000</phone>
      <email>Nero_Evero@Bonfils.org</email>
    </contact>
    <investigator>
      <last_name>Tuan Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny K Schroder</last_name>
      <phone>317-916-5049</phone>
      <email>PSchroeder@indianablood.org</email>
    </contact>
    <investigator>
      <last_name>Dan Waxman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Blood Centers</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa K Reynolds</last_name>
      <phone>651-332-7222</phone>
      <email>Vanessa.Reynolds@innovativeblood.org</email>
    </contact>
    <investigator>
      <last_name>Jed Gorlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Blood Center of Greater Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111-2390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Comes</last_name>
      <phone>816-968-4069</phone>
      <email>jac@cbckc.org</email>
    </contact>
    <investigator>
      <last_name>Beth Shaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoxworth Blood Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeta Rugg, MS</last_name>
      <phone>513-558-1525</phone>
      <email>neeta.rugg@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Cancelas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Graminske</last_name>
      <phone>414-937-6295</phone>
      <email>sharon.graminske@bcw.edu</email>
    </contact>
    <investigator>
      <last_name>Mehraboon Irani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 8, 2016</lastchanged_date>
  <firstreceived_date>April 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
